Welcome to our dedicated page for Ocular Therapeut news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeut stock.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) generates frequent news as an ophthalmology-focused biopharmaceutical company advancing late-stage retinal programs and a commercial eye-care product. Its press releases highlight progress across the AXPAXLI (OTX-TKI) clinical programs in wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR), as well as updates related to DEXTENZA, financings, and corporate events.
News coverage for OCUL commonly includes clinical milestones such as target randomization in the SOL-R Phase 3 wet AMD trial, completion of randomization in SOL-1, and the initiation or advancement of the HELIOS Phase 3 registrational program in NPDR. The company also issues announcements about regulatory strategy, including Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration for SOL-1 and HELIOS-2 and plans to leverage the 505(b)(2) pathway for AXPAXLI in wet AMD.
Investors following OCUL news will see regular business and capital markets updates, such as underwritten equity offerings, cash runway disclosures, and inducement equity grants under Nasdaq Listing Rule 5635(c)(4). The company also reports quarterly financial results and business highlights, describing clinical execution, trial timelines, and planned extension studies like SOL-X for long-term evaluation of AXPAXLI in wet AMD.
In addition, Ocular Therapeutix announces participation in scientific and investor conferences, where it presents data from earlier-stage trials (for example, HELIOS Phase 1 results in NPDR) and discusses its strategy to "redefine the retina experience." For a consolidated view of these developments, the OCUL news page on Stock Titan brings together clinical, regulatory, financial, and corporate communications so readers can track how trial outcomes, regulatory interactions, and financing activities may shape the company’s ophthalmic pipeline and commercial portfolio over time.
Ocular Therapeutix (NASDAQ: OCUL) will host an Investor Day on June 13, 2024, at 2:00 PM ET, both in-person and virtually. The event will feature key opinion leaders Dr. Baruch D. Kuppermann and Dr. Dilsher S. Dhoot, focusing on the company's corporate strategy, clinical data, and development plans for AXPAXLI™. Presentations will include updates on clinical programs for wet AMD and NPDR, specifically the SOL-1 study and Phase 1 HELIOS data. The event will conclude with a Q&A session and a networking reception. A live webcast and a 30-day replay will be available on the company's website.
Ocular Therapeutix (NASDAQ:OCUL), a biopharmaceutical company focused on eye diseases, announced inducement grants for its new Chief Medical Officer, Dr. Nadia K. Waheed, and six other new hires. Dr. Waheed received a non-statutory stock option for 425,000 shares and a restricted stock unit (RSU) award for 141,666 shares, effective June 1, 2024. These options vest over four years and RSUs over three years. Six additional employees received combined stock options for 36,000 shares and RSUs for 12,001 shares, effective June 3, 2024, under the same vesting schedule. The grants are part of Ocular’s 2019 Inducement Stock Incentive Plan, following Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix reported its first-quarter 2024 results, highlighting progress towards becoming a leading retinal care company. Recent achievements include leadership appointments, successful financing, and positive Phase 3 program advances. Cash balance of $482.9 million supports operations until 2028. Revenue increased by 10.4% to $14.8 million, driven by DEXTENZA sales. However, net loss widened to $(64.8) million, attributed to higher expenses.
Ocular Therapeutix, Inc. announced inducement awards to new employees, including the Vice President of Programming & Data Operations and the Vice President of Biostatistics. The awards were granted under the Nasdaq Listing Rule 5635(c)(4) as material to the employees' acceptance of employment.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) will be presenting at two upcoming investor conferences in May 2024. The company is dedicated to developing and commercializing innovative therapies for eye diseases like wet AMD and diabetic retinopathy to improve people's vision and quality of life.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) will be presenting at the OIS Retina and ARVO meetings in Seattle, Washington, from May 4-9, 2024. The Company will showcase its innovative therapies for wet age-related macular degeneration and diabetic retinopathy, with multiple presentations scheduled at the events.
Ocular Therapeutix™ announced plans to report first quarter 2024 financial results on May 7, 2024, and host an Investor Day in New York City on June 13, 2024. The event will focus on the company's corporate strategy and retinal disease pipeline.
Summary not available.
Summary not available.
Summary not available.